For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  GHRP-6
Performance & Muscleearly_human

GHRP-6

Growth Hormone-Releasing Peptide 6
Performance & Muscle
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Performance & Muscle
Evidence grade
C
PubMed records
671
Female-tagged
163
Sex-analysis
2
CAS
—
C
Evidence grade C, Early human data only (Phase 1 / small-n) across 671 indexed studies. How grades work →
Female evidence: Extrapolated
GHRP-6: of 671 PubMed records, 163 are tagged as including female subjects and 2 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic growth-hormone-releasing peptide and one of the earliest secretagogues characterized in endocrine research. Its small, well-studied structure gives it a research-friendly profile as a reference tool compound.

In preclinical and in-vitro systems, GHRP-6 has been studied for its activity at the ghrelin/growth-hormone secretagogue receptor (GHS-R1a) and its role in ghrelin-receptor-mediated growth-hormone release. Researchers examining secretagogue signaling and appetite-related pathways have used it as a research material to characterize how receptor activation couples to downstream growth-hormone and feeding-regulation models.

What makes GHRP-6 a useful entry for an endocrine research catalog is its status as a well-characterized ghrelin-receptor agonist that anchors comparisons across newer secretagogues. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women. Supplied for in-vitro and laboratory research only.

Summary

GHRP-6 is a growth-hormone secretagogue studied in human pharmacology for growth-hormone release and, more recently, tissue-protective effects. It has never been approved as a therapy, and its human literature is not analyzed by sex.

Evidence in women

Menstrual cycle
Unstudied
GH secretion is estrogen-sensitive, but GHRP-6 response has not been mapped across cycle phases.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data; GH-axis stimulation in pregnancy has not been evaluated.
Hormonal interactions
Unstudied
No controlled data on interactions with estrogen or contraceptives.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal studies.
Sex differences
Unstudied
Women were included in pharmacology studies, but outcomes were not systematically analyzed by sex.

Mechanism

Stimulates growth-hormone release via the ghrelin/GHS receptor; also studied for direct cytoprotective (CD36-mediated) effects.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Microgram-per-kilogram doses used in short-term human GH-response studies; no approved therapeutic dose.
Routessubcutaneous, intravenous
Female-specific dosingNot established

Contraindications: active malignancy (GH-axis stimulation, theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

increased appetitetransient cortisol and prolactin increaseflushing

GHRP-6 reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for GHRP-6

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from GHRP-6's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is GHRP-6?

GHRP-6, also known as Growth Hormone-Releasing Peptide 6, is a research compound in our performance muscle category. GHRP-6 is a growth-hormone secretagogue studied in human pharmacology for growth-hormone release and, more recently, tissue-protective effects.

Is GHRP-6 studied in women?

GHRP-6: of 671 PubMed records, 163 are tagged as including female subjects and 2 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has GHRP-6 been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data; GH-axis stimulation in pregnancy has not been evaluated. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does GHRP-6 have, and why?

GHRP-6 carries evidence grade C. Early human data only (Phase 1 / small-n) across 671 indexed studies.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for GHRP-6?

No. A female-specific dose for GHRP-6 is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is GHRP-6 administered in research?

In the published literature, GHRP-6 is administered via subcutaneous, intravenous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for GHRP-6?

Effects reported in the research literature include increased appetite, transient cortisol and prolactin increase, flushing. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should GHRP-6 be stored and handled?

GHRP-6 sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy GHRP-6 for research?

GHRP-6 is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: GHRP-6 isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

28400207 · 9186261

Related peptides

2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
ACE-031C
ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag.
AICARB
AICAR: of 2,496 PubMed records, 329 are tagged as including female subjects and 2 carry a sex-analysis tag.
CJC-1295 with DACC
CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.